Avadel Pharmaceuticals PLC (AVDL)

NASDAQ
6.750
-0.060(-0.88%)
Pre Market
6.750
0.000(0.00%)
- Real-time Data
  • Volume:
    381,131
  • Day's Range:
    6.433 - 6.825
  • 52 wk Range:
    1.050 - 11.590

AVDL Overview

Prev. Close
6.81
Day's Range
6.433-6.825
Revenue
-
Open
6.79
52 wk Range
1.05-11.59
EPS
-2.28
Volume
381,131
Market Cap
403.61M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,030,753
P/E Ratio
-3.04
Beta
1.51
1-Year Change
-8.04%
Shares Outstanding
59,793,371
Next Earnings Date
Nov 07, 2022
What is your sentiment on Avadel Pharma?
or
Market is currently closed. Voting is open during market hours.

Avadel Pharmaceuticals PLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Avadel Pharmaceuticals PLC Analysis

Avadel Pharmaceuticals PLC Company Profile

Avadel Pharmaceuticals PLC Company Profile

Employees
32

Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyBuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • We're back :)
    0
    • who knows what is happining in the shadows with this company?
      0
      • Who knows what is happining in the shadows with this company?
        0
        • Brace yourselves
          0
          • Huge movements, what the **** is happening D: I like it
            0
            • "DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th." https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-participate-fireside-chat-10th-annual-svb
              0
              • what do you think about this one?
                0
                • im in love with it
                  0
                • gambling...
                  0
              • This is a possible ten bagger if FDA aproves ft218
                0
                • that was news in Dec
                  0
                • In december they submited to FDA for aproval. It hasn't been aproved yet
                  0
              • What do you think about this stock after Oppenheimer Fall Healthcare of yesterday ?
                0
                • "Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy"... Pre Market +30-50%
                  0